NDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
TORADOL (ketorolac tromethamine) by Roche is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. First approved in 1991.
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORADOL (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) administered orally as a tablet for short-term management of moderate to severe acute pain. It works by inhibiting prostaglandin synthetase, with the S-enantiomer providing analgesic activity; peak effect occurs within 2–3 hours with no sedative properties.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure; commercial team sizing likely contracting as market becomes commoditized.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on TORADOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.